Allergy Therapeutics Stumped As Birch Product Fails At Phase III
A strong immunological response to the PQ Birch vaccine did not translate into any appreciable reduction in symptoms in the Phase III trial, leaving the UK firm perplexed, and its share price southwards.
You may also be interested in...
Allergy Therapeutics says it has learned lessons from its failed Phase III birch pollen allergy trial and is applying those to its pivotal grass Phase III study.
A marketing approval for a seasonal allergic rhinitis vaccine from Allergy Therapeutics has moved nearer with positive top-line Phase II results that define the dose to be used in a Phase III study.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.